PeptideStack
5.2kquestions
20kanswers
220users

What is the dead-space loss per draw with an 18G drawing needle at 10 mg/mL?

Asked 8 Oct 2025Modified 8 months agoViewed 16k times
14

Details up front: an 18G drawing needle · 10 mg/mL.

I can do the algebra. I am not confident about the conversion factors.

If there is a standard way to lay this out, I would rather learn that than invent one.

Can someone walk through the arithmetic step by step?

dead-space
dead-space

The volume trapped in the syringe hub and needle after the plunger bottoms out. It is small in absolute terms and large as a fraction of a small…

117 questions
insulin-syringe
insulin-syringe

U-100 and U-40 insulin syringes as measuring instruments. A U-100 syringe is graduated in insulin units where 100 units equals 1 mL, so one unit…

244 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
shareeditfollowflag
LC
askedlyoph_cake78k2678 Oct 2025

5 Answers

Sorted by votes
23

At 10 mg/mL every microlitre left behind is 10 µg, so a 50 µL hub costs 0.5 mg per draw and a 5 µL fixed-needle barrel costs 0.05 mg. Multiply by the draws, not by the doses: ten draws through a 50 µL dead space is 5 mg gone, which at 10 mg/mL is 0.5 mL of solution you paid for and never administered. Against a 2 mg dose that 50 µL is 25 per cent; against a 0.25 mg dose it is 200 per cent, which is why the loss matters most at exactly the doses where you can least afford it. an 18G drawing needle has a bore, a hub and a length, and the hub dominates: a fixed-needle insulin barrel has almost none, a luer connection has a measurable one before the needle even starts.

Put another way, dead space is the volume trapped in the syringe hub and needle after the plunger bottoms out, and it is the reason your 10 mg vial yields only 9.5 mg of usable draws.

Be sceptical of anything advertised as low dead space that retains a conventional plunger tip: if you can look into the fitting with the plunger fully forward and see an open conical void, that void is your dead space.

Corollary that follows immediately: changing needle gauge or length barely changes your losses.

If cost matters, this is the first thing to change, not the last.

shareimprove this answerflag
NT
answeredn_takahashi29k3821 Oct 2025
7Would this be different for a peptide that foams? Mine does and I have never known why. – Dr_Marek_Zielinski 3 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
16

The relevant detail is that the switch to a low-dead-space syringe nearly doubles your usable vial, which is better than switching suppliers if you are looking for cost savings.

Configuration B — 0.5 mL fixed-needle U-100 insulin syringe, dead space 2 µL: volume removed per draw = 100 + 2 = 102 µL.

Specifically, the needle lumen volume is under a microlitre in a typical fine-gauge configuration, so the needle is not the problem.

The caveat is that dead space is a yield loss and not a dose-accuracy loss, so the person feeling this loss most is the person with the most total draws.

The switch nearly doubles your vial, which is better than most other optimisations combined.

shareimprove this answerflag
TN
answeredtabular_nums71k4810 Oct 2025
13

Concretely, this is arithmetic, so let us do the arithmetic and see where the losses actually are.

Low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.

Draws available = 2000 / 102 = 19.6, so 19 full draws. Delivered peptide = 19 x 0.5 mg = 9.5 mg. Lost to dead space = 19 x 2 µL = 38 µL x 0.005 = 0.19 mg. Yield = 95 per cent.

Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.

The limitation is that even with perfect technique, some loss is irreducible unless you switch to a low-dead-space syringe.

Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.

edited 9 Dec 2025 by u100_marks — added the placebo-arm figures

shareimprove this answerflag
UM
answeredu100_marks52k3712 Nov 2025
4This should be linked from the help pages. – net_peptide 2 months ago
add a comment
11

Changing syringe architecture changes everything, while changing needle gauge changes almost nothing.

The complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.

Worth noting: draw size matters enormously — the smaller your draws, the more the syringe architecture matters.

Write the arithmetic on the vial label. It costs nothing and it removes the step where you reconstruct it from memory at an inconvenient moment.

shareimprove this answerflag
LS
answeredlow_dead_space37k371 Nov 2025
6Confirming: I did the wrong thing here once and got exactly the predicted result. – Dr_Marek_Zielinski 10 months ago
7Two of us worked through this independently and arrived here, so at least it reproduces. – kwn_analytical 40 days ago
add a comment
6

The short answer is that dead space is small in absolute terms and huge as a fraction of a small dose, which is why it feels like a rounding error and behaves like a systematic loss.

At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.

The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.

The practical summary: fine gauge, gentle swirl, diluent down the wall, room temperature before drawing, and check the syringe scale against the barrel rather than against your assumption.

shareimprove this answerflag
TO
answeredt_oyelaran79k485 Dec 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.